January 22, 2018 Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker Tucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (E
January 17, 2018 C-Path welcomes Kay Holcombe to its Board of Directors January 17, 2018 TUCSON, Ariz., January 17, 2018 — The Critical Path Institute (C-Path) is pleased to welcome Kay Holcombe to i
January 9, 2018 Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis
January 9, 2018 Training on the use of technology to collect patient-reported outcome data electronically in clinical trials: best practice recommendations from the ePRO Consortium Ly, JJ, Crescioni, M, Eremenco, S, Bodart, S, Donoso, M, Butler, AJ, et al. Training on the use of technology to collect patient-r
January 6, 2018 Selection of and evidentiary considerations for wearable devices and their measurements for use in regulatory decision making: recommendations from the ePRO Consortium
January 6, 2018 Informing the tolerability of cancer treatments using patient-reported outcome (PRO) measures: summary of an FDA and Critical Path Institute workshop
January 6, 2018 Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study
January 1, 2018 Development of a symptom-focused patient-reported outcome measure for functional dyspepsia: the Functional Dyspepsia Symptom Diary (FDSD)
January 1, 2018 Performance Assessment of New Urinary Translational Safety Biomarkers of Drug-induced Renal Tubular Injury in Tenofovir-treated Cynomolgus Monkeys and Beagle Dogs